HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supplement Adverse Event Reports Grow, But FDA Says 'Serious' Intel Is Short

This article was originally published in The Rose Sheet

Executive Summary

Serious AERs submitted to FDA have plateaued since 2010, though reports the agency receives from consumers steadily increased. While FDA suspects supplement firms are not providing all serious AERs as required, stakeholders say the agency overestimates the number of serious AERs.

You may also be interested in...

Robust Internal AER Systems Follow Supplement Lifecycle – Nature's Bounty Expert

Robust dietary supplement adverse event compliance systems can support faster identification of problems and improve products, says Nature’s Bounty Product Vigilance Manager Christina Romano. During a recent CRN webinar, she said distributors, retailers and researchers should be part of the reporting system.

Causation Disclaimers Should Be In Adverse Event Reports Submitted To FDA

Dietary supplement firms should use a script for receiving AERs and establish review protocols to ensure serious events are reported to FDA, recommends attorney Claudia Lewis. She detailed best practices for supplement AERs at a recent American Conference Institute conference.

Bipartisan AER Bill Requires Reporting For All OTC Drugs, Supplements

Manufacturers of nonprescription drugs and dietary supplements will have to provide company contact information on product labels in order for consumers to report serious adverse events associated with the products under long-awaited legislation introduced June 21


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts